Related coverage linked through entity extraction aliases.
May 05, 2026
San Francisco's RESET Center opens Monday in SoMa to take in people found publicly using drugs or intoxicated. Officials have offered conflicting explanations about arrest status, detention, release rules and medication access.
Apr 28, 2026
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Feb 24, 2026
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
